Loading [Contrib]/a11y/accessibility-menu.js

Ophthalmology

The Association of Retinal Disease with Vision Impairment and Functional Status in Medicare Patients
March 29, 2024 EDT
The Association of Retinal Disease with Vision Impairment and Functional Status in Medicare Patients
Vincent GarmoXiaohui ZhaoCarmen D. NgAimee NearTania BanerjiKeiko WadaGary OderdaDiana BrixnerJoseph BiskupiakFerhina S. AliArchad M. KhananiAlicia MenezesIbrahim M. Abbass

This study examined patient-reported survey data linked with Medicare claims to describe the burden of these vision-threatening retinal diseases among Medicare beneficiaries.

Comparing Prednisone and Methotrexate to Off-label Biologic Infliximab for Management of Ocular Uveitis: A Cost-minimization Analysis
January 20, 2015 EDT
Comparing Prednisone and Methotrexate to Off-label Biologic Infliximab for Management of Ocular Uveitis: A Cost-minimization Analysis
William V. PadulaMiguel Cordero-ComaTaygan YilmazWilliam V. PadulaMichéal J. GallagherJonathan D. Campbell

To evaluate whether infliximab, a modern off-label biologic, is cost-effective for treating posterior uveitis and panuveitis compared to current standards of care, methotrexate and prednisone.

Anti-vascular Endothelial Growth Factor Outpatient Treatment Patterns in Patients with Exudative Age-related Macular Degeneration from a Japanese Hospital Claims Database
July 08, 2014 EDT
Anti-vascular Endothelial Growth Factor Outpatient Treatment Patterns in Patients with Exudative Age-related Macular Degeneration from a Japanese Hospital Claims Database
Tomohiro IidaAya NarimatsuKenji AdachiEdward CY Wang

To identify outpatient treatment patterns of patients with exudative age-related macular degeneration (AMD) who received approved anti–vascular endothelial growth factor (VEGF) therapy, using real-world data from hospitals in Japan.